Mainz Biomed NV (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today a partnership with Dr Staber & Kollegen GmbH (Labor Staber) as part of its growing network of laboratories offering ColoAlert, its flagship product that is a highly efficacious and easy-to-use at-home screening test for colorectal cancer (CRC). For more than 35 years, Labor Staber has been providing physicians and hospitals with medical laboratory services at nine locations across Germany.
Tailwind Acquisition Corp. Reminds Shareholders To Vote In Favor Of Proposed Deal With QOMPLX
Special Meeting of Tailwind stockholders to approve proposed business combination with QOMPLX to be held on July 20, 2021
Stockholders of record as of the close of business on June 2, 2021 should vote their shares even
